Business Context and Reporting Period
This Form 8-K, dated April 1, 2014, reports on Imprimis Pharmaceuticals, Inc. (the "Company"). The filing details the completion of an asset acquisition on April 1, 2014. Note: The request metadata references "Harrow, Inc.," but the filing text explicitly identifies the registrant as Imprimis Pharmaceuticals, Inc.
Key Financial Metrics and Transaction Details
- Acquisition Target: Pharmacy Creations, LLC, a New Jersey compounding pharmacy licensed to ship to 17 U.S. states, Washington D.C., Puerto Rico, and Canada.
- Upfront Cash Consideration: $600,000 paid to sellers at closing.
- Price Adjustment: The cash purchase price is subject to adjustment based on Pharmacy Creations' EBITDA for the fiscal year ended December 31, 2013.
- Contingent Cash Consideration: Up to $50,000 payable if revenue exceeds $3,500,000 for the 12-month period ending March 31, 2015.
- Contingent Stock Consideration: Up to 215,910 shares of common stock issuable based on revenue milestones for the 12-month period ending March 31, 2016 (full amount if revenue exceeds $7,500,000; pro-rated if between $3,500,000 and $7,500,000).
- Required Investment: The Company is contractually obligated to invest $1,000,000 by March 31, 2016, in facilities, personnel, equipment, and marketing for the acquired entity.
Material Changes
The primary material change is the expansion of the Company's operational footprint through the acquisition of Pharmacy Creations. The filing does not provide comparative financial statements for the prior period or specific revenue/profit figures for the Company or the acquired entity prior to this transaction.
Outlook, Risks, and Contingencies
- Future Obligations: The Company faces a mandatory capital expenditure obligation of $1,000,000 within two years.
- Performance Contingencies: Future cash and equity outflows depend entirely on Pharmacy Creations meeting specific revenue thresholds in 2015 and 2016.
- Licensing: Pharmacy Creations has pending license applications in 16 additional U.S. states and is pursuing licensure in remaining states, representing potential growth but also regulatory uncertainty.
- Financial Reporting: Pro forma financial information and specific financial statements for the acquired business are not included in this filing and will be filed separately as required.
Investor Verification Checklist
- Verify the final EBITDA calculation for Pharmacy Creations for the fiscal year ended December 31, 2013, to determine the final adjusted cash purchase price.
- Monitor the Company's capital allocation to ensure the $1,000,000 investment commitment is met by March 31, 2016.
- Track Pharmacy Creations' revenue performance against the $3.5 million and $7.5 million milestones to assess potential dilution from contingent stock issuance.
- Review the status of pending pharmacy license applications in the 16 states mentioned to evaluate regulatory risk.
- Wait for the subsequent filing of pro forma financial information to understand the full financial impact of the acquisition.